NTBL: AI 评分 64/100 — AI 分析 (4月 2026)

Notable Labs, Ltd. is a clinical-stage platform therapeutics company focused on developing predictive precision medicines for cancer patients. Their PPMP platform aims to identify patients likely to respond to specific therapies, accelerating clinical development.

Key Facts: Price: $0.25 AI Score: 64/100 Sector: Healthcare

公司概况

概要：

Notable Labs (NTBL) pioneers predictive precision medicine for cancer, leveraging its proprietary PPMP platform to personalize treatment and accelerate drug development, offering a targeted approach to oncology therapeutics and potentially disrupting traditional clinical trial paradigms.

NTBL是做什么的？

Notable Labs, Ltd., operates as a clinical-stage platform therapeutics company dedicated to transforming cancer treatment through predictive precision medicine. Founded with the vision of shifting away from the traditional 'one-size-fits-all' approach, Notable Labs has developed a proprietary Predictive Precision Medicines Platform (PPMP). This innovative platform bio-simulates cancer treatments to predict patient responsiveness, enabling the selection of individuals most likely to benefit from specific therapies. The company's PPMP is designed to fast-track clinical development by focusing on clinically responsive patients. Notable Labs' pipeline features Volasertib, a Polo-like kinase 1 (PLK-1) inhibitor targeting acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, they are developing Fosciclopirox, a pro-drug of ciclopirox, also for AML. Headquartered in Or-Yehuda, Israel, Notable Labs is committed to advancing personalized cancer care through its unique predictive platform.

NTBL的投资论点是什么？

Notable Labs presents a notable market position due to its innovative PPMP platform, which has the potential to revolutionize cancer treatment by predicting patient response to therapies. The company's focus on precision medicine addresses a critical need in oncology, potentially leading to faster and more efficient clinical trials and improved patient outcomes. With a Gross Margin of 36.5%, Notable Labs demonstrates the potential for profitability as its pipeline progresses. Key catalysts include the advancement of Volasertib and Fosciclopirox through clinical trials, with potential FDA milestones driving significant value. The company's ability to identify responsive patients could lead to accelerated approval pathways and increased market adoption, making NTBL an attractive investment in the biotechnology sector.

NTBL在哪个行业运营？

The biotechnology industry is undergoing a shift towards personalized medicine, driven by advancements in genomics and diagnostics. Companies like Notable Labs, with their focus on predictive precision medicine, are at the forefront of this trend. The competitive landscape includes companies developing targeted therapies and diagnostic tools. The market for personalized cancer treatments is expected to grow significantly, driven by the increasing prevalence of cancer and the demand for more effective and less toxic therapies. Notable Labs' PPMP platform positions it to capitalize on this growth by enabling the development of more targeted and effective cancer treatments.

Biotechnology

Healthcare

NTBL有哪些增长机遇？

Expansion of PPMP Platform: Notable Labs can expand the application of its PPMP platform to other cancer types beyond AML, pediatric leukemia, and myelodysplastic syndromes. This expansion would significantly increase the addressable market and revenue potential. The global oncology market is projected to reach $286.6 billion by 2030, providing a substantial opportunity for growth. Timeline: Ongoing, with continuous research and development efforts.
Strategic Partnerships: Collaborating with pharmaceutical companies to utilize the PPMP platform in their drug development programs. This would provide Notable Labs with upfront payments, milestone payments, and royalties on future sales. Many large pharmaceutical companies are actively seeking innovative technologies to improve their drug development success rates. Timeline: Within the next 1-2 years.
Advancement of Volasertib: Progressing Volasertib through clinical trials and obtaining regulatory approval for AML, pediatric leukemia, and myelodysplastic syndromes. Successful commercialization of Volasertib would generate significant revenue. The market for AML therapeutics is expected to grow, driven by the increasing incidence of the disease. Timeline: 3-5 years, depending on clinical trial outcomes and regulatory review.
Development of Fosciclopirox: Advancing Fosciclopirox through clinical trials and obtaining regulatory approval for AML. Fosciclopirox represents another potential revenue stream for Notable Labs. The AML therapeutics market is competitive, but there is a need for new and more effective treatments. Timeline: 3-5 years, depending on clinical trial outcomes and regulatory review.
Personalized Medicine Expansion: Leveraging the PPMP platform to develop personalized treatment plans for individual cancer patients. This would involve analyzing patient-specific data to identify the most effective therapies. The personalized medicine market is growing rapidly, driven by the increasing availability of genomic and other patient data. Timeline: Ongoing, with continuous development of the PPMP platform.

Proprietary Predictive Precision Medicines Platform (PPMP) enables personalized cancer treatment strategies.
Pipeline includes Volasertib, a PLK-1 inhibitor targeting AML, pediatric leukemia, and myelodysplastic syndromes.
Fosciclopirox, a pro-drug of ciclopirox, is being developed for AML.
Gross Margin of 36.5% indicates potential for future profitability.
Headquartered in Or-Yehuda, Israel, positioning the company in a growing biotech hub.

NTBL提供哪些产品和服务？

Develop predictive precision medicines for cancer patients.
Utilize a proprietary Predictive Precision Medicines Platform (PPMP).
Bio-simulate cancer treatments to predict patient responsiveness.
Identify and select clinically responsive patients prior to treatment.
Fast-track clinical development by focusing on responsive patients.
Develop Volasertib, a PLK-1 inhibitor for AML, pediatric leukemia, and myelodysplastic syndromes.
Develop Fosciclopirox, a pro-drug of ciclopirox for AML.

NTBL如何赚钱？

Develop and commercialize predictive precision medicines.
Generate revenue through sales of approved therapies.
Establish strategic partnerships with pharmaceutical companies.
Receive upfront payments, milestone payments, and royalties.

Cancer patients.
Hospitals and oncology clinics.
Pharmaceutical companies.

Proprietary Predictive Precision Medicines Platform (PPMP).
Ability to predict patient responsiveness to therapies.
Focus on personalized cancer treatment.
Pipeline of novel cancer therapeutics.

什么因素可能推动NTBL股价上涨？

Upcoming: Clinical trial results for Volasertib in AML, pediatric leukemia, and myelodysplastic syndromes.
Upcoming: Clinical trial results for Fosciclopirox in AML.
Upcoming: Potential FDA approval of Volasertib or Fosciclopirox.
Ongoing: Expansion of PPMP platform to other cancer types.
Ongoing: Strategic partnerships with pharmaceutical companies.

NTBL的主要风险是什么？

Potential: Unsuccessful clinical trial outcomes for Volasertib or Fosciclopirox.
Potential: Regulatory delays or rejection of Volasertib or Fosciclopirox.
Potential: Competition from other biotechnology companies.
Ongoing: High research and development costs.
Ongoing: Dependence on securing additional funding.

NTBL的核心优势是什么？

Proprietary Predictive Precision Medicines Platform (PPMP).
Focus on personalized cancer treatment.
Pipeline of novel cancer therapeutics.
Potential to accelerate clinical development.

NTBL的劣势是什么？

Clinical-stage company with no approved products.
High research and development costs.
Dependence on successful clinical trial outcomes.
Negative Profit Margin of -3633.5%.

NTBL有哪些机遇？

Expansion of PPMP platform to other cancer types.
Strategic partnerships with pharmaceutical companies.
Advancement of Volasertib and Fosciclopirox through clinical trials.
Personalized medicine expansion.

NTBL面临哪些威胁？

Competition from other biotechnology companies.
Regulatory hurdles and delays.
Unsuccessful clinical trial outcomes.
Potential for product liability claims.

NTBL的竞争对手是谁？

Aravive, Inc. — Focuses on developing therapies for oncology and fibrotic diseases. — (ARAV)
Athenex, Inc. — Develops therapies for cancer. — (ATNX)
Biophytis S.A. — Develops therapeutics for age-related macular degeneration and sarcopenia. — (BPTS)
Eiger BioPharmaceuticals, Inc. — Focuses on developing therapies for rare diseases. — (EIGRQ)
Fresenius SE & Co. KGaA — Provides products and services for dialysis, hospitals and outpatient medical care. — (FRES)

Key Metrics

Price: $0.25 (-27.68%)
Market Cap: $3.0M
MoonshotScore: 64/100

常见问题

What does Notable Labs, Ltd. (NTBL) do?

Notable Labs, Ltd. is a clinical-stage biotechnology company focused on developing predictive precision medicines for cancer. Their core technology is the Predictive Precision Medicines Platform (PPMP), which simulates cancer treatments to predict how individual patients will respond. This allows them to identify patients most likely to benefit from specific therapies, potentially accelerating clinical trials and improving treatment outcomes. Their pipeline includes Volasertib and Fosciclopirox, both targeting acute myeloid leukemia (AML) and other related conditions.

Is NTBL stock a good buy?

Evaluating whether NTBL stock is a good buy requires careful consideration. The company's innovative PPMP platform and focus on personalized medicine offer significant potential, but as a clinical-stage company, it carries substantial risk. While the Gross Margin is 36.5%, the negative P/E ratio of -0.05 and a negative Profit Margin of -3633.5% highlight the current lack of profitability. Investors should weigh the potential for future growth against the inherent risks of biotechnology investments.

What are the risks of investing in NTBL?

Investing in NTBL carries several risks typical of clinical-stage biotechnology companies. These include the risk of unsuccessful clinical trial outcomes for their lead drug candidates, Volasertib and Fosciclopirox. Regulatory hurdles and potential delays in FDA approval also pose significant risks. Furthermore, the company faces competition from other biotechnology firms and relies on securing additional funding to support its research and development efforts. The company's high cash burn rate and potential for dilution are also important considerations.

What catalysts could move NTBL stock?

Several catalysts could potentially drive NTBL stock price. Positive results from ongoing clinical trials of Volasertib and Fosciclopirox are key near-term catalysts. Achieving significant milestones in these trials, such as demonstrating efficacy and safety, could boost investor confidence. Furthermore, any news regarding potential FDA approval for either drug would likely have a substantial positive impact. Strategic partnerships with larger pharmaceutical companies could also serve as catalysts, validating the company's technology and providing additional funding.

What is NTBL stock price target?

As of March 2, 2026, there is no readily available analyst consensus price target for NTBL stock, likely due to its micro-cap status and limited coverage. Given the lack of analyst coverage, it is difficult to provide a definitive price target. Investors should conduct their own due diligence and consider the company's fundamentals, pipeline progress, and overall market conditions to determine a fair value estimate.